A single infusion of a therapy borrowed from cancer treatment sent three of six patients with severe rheumatoid arthritis into full remission without any medication. All six saw their disease activity fall.
The results, from the Phase 1 COMPARE trial at Charité - Universitätsmedizin Berlin in Germany, were published in Nature Medicine in late August 2026.
Every participant had run out of options after failing up to eight prior therapies. Follow-up so far reaches up to one year.
The treatment is a CD19-directed CAR-T cell therapy called mivocabtagene autoleucel. In CAR-T therapy, a patient's own T cells are collected, genetically engineered to seek out specific target cells, then infused back into the body.
Also read: These habits can leave you feeling stuck and exhausted
The approach is already established in certain blood cancers.
Cancer therapy might reset an autoimmune disease
Rheumatoid arthritis is driven by immune cells, especially B cells, that attack the joints and cause inflammation, pain and joint damage over time. Most patients depend on lifelong immunosuppressive medication to keep symptoms in check.
The engineered T cells target a marker called CD19 on B cells, wiping out the population that fuels the autoimmune attack. When B cells later regenerate, the harmful "memory" cells that drove the disease do not come back with them.
Autoantibody levels dropped by more than 90 percent, and protective antibodies from past vaccinations against chickenpox and tetanus were still detectable afterward.
Also read: Night owls may carry a mental health burden that morning people do not face
What the small trial cannot yet answer
Six patients is a very small sample. The Phase 1 stage is designed to test safety and early signals, not to prove the therapy works broadly.
Rheumatoid arthritis affects millions of Americans, and most rely on drugs they cannot stop taking.
Anyone concerned about the warning signs of rheumatoid arthritis should discuss them with a doctor rather than change any treatment plan on their own.
The safety profile in the Berlin cohort was described as manageable. Participants had a mild-to-moderate cytokine release syndrome, a temporary immune reaction common after CAR-T infusion, and no severe neurological complications or unexpected toxicities were reported.
Also read: Drinking orange juice every day may change thousands of your body's genes
Also read: Quitting alcohol may not be enough to heal your liver, research reveals
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.